<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Immunogenicity of infliximab and adalimumab

descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 16 Apr 2019 Italy English Publisher:Informa UK LimitedJournal:Expert Opinion on Drug Safety, volume 18, pages 343-345 (issn: 1474-0338, eissn: 1744-764X,

Authors: Murdaca G.; Negrini S.; Greco M.; Schiavi C.; Giusti F.; Borro M.; Puppo F.;

doi: 10.1080/14740338.2019.1602117

pmid: 30938213

handle: 11567/956347 , 2318/2054925

Immunogenicity of infliximab and adalimumab

- Summary
- Subjects
- Metrics

Abstract

TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated dise...

Country

Italy

Related Organizations

Keywords

Tumor Necrosis Factor-alpha, Antirheumatic Agents, adalimumab; biosimilars; hypersensitivity reactions; immunogenicity; Infliximab; Adalimumab; Antirheumatic Agents; Humans; Infliximab; Tumor Necrosis Factor-alpha, Adalimumab, Humans, Infliximab

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	16
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%